Profile data is unavailable for this security.
About the company
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of heparin-related products. The Company's main products include standard heparin raw materials, low molecular weight heparin raw materials and their preparations, such as heparin sodium raw materials, heparin sodium, enoxaparin sodium injection, dalteparin sodium injection and Naqu Heparin Calcium Injection. The Company mainly exports its products to the United States and European countries.
- Revenue in CNY (TTM)3.63bn
- Net income in CNY-344.58m
- Incorporated2000
- Employees1.45k
- LocationNanjing King-friend Biochemical Pharmaceutical Co LtdNo. 16 Xuefu RoadHigh-tech Industrial Development ZoneNANJING 210061ChinaCHN
- Phone+86 2 586990789
- Fax+86 2 586990701
- Websitehttps://www.nkf-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dizal Jiangsu Pharmaceutical Co Ltd | 172.61m | -1.09bn | 17.62bn | 581.00 | -- | 25.29 | -- | 102.05 | -2.67 | -2.67 | 0.422 | 1.68 | 0.1008 | 0.3215 | 6.78 | 297,086.40 | -63.79 | -46.02 | -82.62 | -52.99 | 96.41 | 57.53 | -632.90 | -2,081.54 | 1.74 | -- | 0.4557 | -- | -- | 18.29 | -50.50 | -- | 21.35 | -- |
| Tonghua Dongbao Pharmaceutical Co Ltd | 3.00bn | 1.13bn | 18.33bn | 3.20k | 16.28 | 2.48 | -- | 6.11 | 0.5682 | 0.5682 | 1.51 | 3.73 | 0.403 | 0.8622 | 4.57 | 939,125.30 | 15.20 | 18.68 | 15.84 | 19.68 | 79.89 | 78.73 | 37.71 | 39.20 | 5.04 | -- | 0.03 | 41.73 | 10.69 | 2.69 | -26.17 | 6.85 | -14.75 | 4.56 |
| Sinocelltech Group Ltd | 2.17bn | -168.81m | 19.35bn | 2.33k | -- | -- | -- | 8.91 | -0.3791 | -0.3791 | 4.88 | -1.16 | 0.761 | 0.3743 | 6.86 | 930,592.90 | -5.93 | -40.17 | -15.48 | -74.63 | 96.35 | 95.42 | -7.79 | -108.20 | 0.4649 | 3.33 | 1.23 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
| Tasly Pharmaceutical Group Co Ltd | 8.64bn | 1.10bn | 20.69bn | 9.22k | 18.86 | 1.63 | -- | 2.39 | 0.7342 | 0.7342 | 5.77 | 8.47 | 0.4899 | 1.72 | 10.80 | 937,046.80 | 5.93 | 5.47 | 7.21 | 7.25 | 65.67 | 48.42 | 12.11 | 8.94 | 2.73 | 5.91 | 0.2083 | 50.99 | 0.4236 | -13.57 | 505.34 | -7.07 | -3.03 | 1.92 |
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 3.63bn | -344.58m | 20.77bn | 1.45k | -- | 3.46 | -- | 5.73 | -0.2727 | -0.2727 | 2.30 | 3.71 | 0.3561 | 0.4354 | 3.35 | 2,500,466.00 | -3.38 | 8.97 | -4.83 | 13.15 | 43.57 | 45.59 | -9.50 | 20.12 | 1.15 | -- | 0.3129 | 26.33 | 5.89 | 18.25 | -117.37 | -- | 38.32 | 13.75 |
| Chongqing Taiji Industry Group Co Ltd | 15.40bn | 834.00m | 21.20bn | 12.59k | 25.42 | 5.48 | -- | 1.38 | 1.50 | 1.50 | 27.66 | 6.95 | 1.03 | 3.15 | 5.84 | 1,223,535.00 | 5.77 | 0.7814 | 17.83 | 2.35 | 46.14 | 44.03 | 5.62 | 0.8498 | 0.5315 | 6.12 | 0.5393 | 25.76 | 10.58 | 7.88 | 131.99 | 63.55 | 3.86 | 24.57 |
| Xiamen Amoytop Biotech Co Ltd | 2.23bn | 600.08m | 21.83bn | 1.96k | 36.38 | 10.89 | -- | 9.80 | 1.48 | 1.48 | 5.47 | 4.93 | 1.04 | 0.8541 | 6.70 | 1,135,877.00 | 28.09 | 17.96 | 32.72 | 21.02 | 93.17 | 90.48 | 26.95 | 19.17 | 3.22 | -- | 0.0037 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
| China Resources Dubl-Crne Phrmctl Co Ltd | 10.32bn | 1.38bn | 22.38bn | 12.27k | 16.05 | 1.92 | -- | 2.17 | 1.34 | 1.34 | 10.07 | 11.24 | 0.6781 | 2.85 | 5.82 | 841,054.60 | 8.87 | 8.58 | 11.67 | 11.21 | 54.25 | 58.19 | 13.08 | 11.98 | 2.15 | -- | 0.0249 | 35.91 | 6.20 | 4.44 | 12.96 | 6.60 | 21.46 | -1.63 |
| Joincare Pharmaceutical Group Ind. Co. | 16.43bn | 1.42bn | 23.48bn | 14.37k | 16.39 | 1.65 | -- | 1.43 | 0.7676 | 0.7676 | 8.86 | 7.63 | 0.4522 | 2.36 | 5.57 | 1,143,551.00 | 7.98 | 8.46 | 16.51 | 18.84 | 61.23 | 62.72 | 17.64 | 17.00 | 2.11 | -- | 0.2247 | 28.86 | -2.90 | 8.24 | -3.99 | 15.58 | 11.53 | 2.38 |
Data as of Jun 07 2024. Currency figures normalised to Nanjing King-friend Biochemical Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
9.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2023 | 67.81m | 4.20% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 2023 | 13.77m | 0.85% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 12.85m | 0.80% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 12.65m | 0.78% |
| Orient Securities Asset Management Co. Ltd.as of 31 Dec 2023 | 12.09m | 0.75% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 10.20m | 0.63% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 9.30m | 0.58% |
| Lion Fund Management Co., Ltd.as of 31 Dec 2023 | 9.13m | 0.57% |
| Qian Hai Life Insurance Co., Ltd.as of 30 Jun 2023 | 7.33m | 0.45% |
| Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 4.81m | 0.30% |
More ▼
Data from 30 Sep 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
